IOP Elevation Study

Description

The purpose of this study is to improve understanding of the pathophysiologic process that leads to the development of glaucamotous damage. The mechanism by which vision loss in glaucoma occurs is still unknown, but it is clear that increased intraocular pressure (IOP) is a major risk factor. It is also thought that the LC is a site of primary damage during pathogenesis of the disease. This prospective study with determine the in-vivo mechanical response to IOP modulation at the level of the ONH and LC.

Conditions

Intraocular Pressure

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to improve understanding of the pathophysiologic process that leads to the development of glaucamotous damage. The mechanism by which vision loss in glaucoma occurs is still unknown, but it is clear that increased intraocular pressure (IOP) is a major risk factor. It is also thought that the LC is a site of primary damage during pathogenesis of the disease. This prospective study with determine the in-vivo mechanical response to IOP modulation at the level of the ONH and LC.

Effects of Elevated Intraocular Pressure on the Lamina Cribrosa

IOP Elevation Study

Condition
Intraocular Pressure
Intervention / Treatment

-

Contacts and Locations

New York

NYU Langone Health, New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * No family history (first degree relative) of glaucoma.
  • * No history of IOP \>22 mmHg.
  • * Normal appearing optic discs and RNFL on dilated fundus examination.
  • * Normal Swedish interactive thresholding algorithm (SITA) standard perimetry tests as defined by glaucoma hemifield test (GHT) within normal limits.
  • * Normal visual field as defined above.
  • * Either IOP between 25 to 30 mmHg with central corneal thickness \< 550µm, or a difference ≥ 0.2 in cup to disc ratio between eyes.
  • * Glaucomatous ONH abnormality: rim thinning, notching, undermining (excavation) or diffuse or localized RNFL defects that are characteristic of glaucoma.
  • * Two consecutive abnormal SITA standard perimetry tests with GHT outside normal limits.
  • * Media opacity (e.g. lens, vitreous, cornea).
  • * Strabismus, nystagmus or a condition that would prevent fixation.
  • * Diabetes with evidence of retinopathy.
  • * Previous intraocular surgery or ocular trauma (with the exception of laser procedures and subjects that have undergone uneventful cataract surgery more than 6 months from enrollment date).
  • * Neurological and non-glaucomatous causes for visual field damage.
  • * Any intraocular non-glaucomatous ocular disorders.

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

NYU Langone Health,

Gadi Wollstein, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

2024-05-08